Search Results

MilliporeSigma and The Michael J. Fox Foundation for Parkinson’s Research (MJFF), are advancing research aimed at slowing progression of Parkinson’s disease (PD).

Kannalife Sciences, Inc. is pleased to announce it has been awarded funding of $1,493,409 million from The Michael J. Fox Foundation for Parkinson’s Research.

The Michael J. Fox Foundation for Parkinson’s Research announced $9.75 million in total awards to five research teams working on tools to biologically measure and track the progression of Parkinson’s disease from its earliest detection through more advanced stages.

bit.bio, the company coding human cells for novel cures, announces the first project within a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease.

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and The Michael J. Fox Foundation for Parkinson’s Research, a non-profit organization dedicated to finding a cure for Parkinson’s disease, announced a research project to accelerate research on genetic risk factors associated with PD, specifically targeting the role of variants in the GBA gene.

Cantabio Pharmaceuticals, Inc. announced that The Michael J. Fox Foundation for Parkinson’s Research has awarded the Company a major grant for a project entitled “Development of Cell-penetrant DJ-1 Protein as a Therapeutic Candidate for Treatment of Parkinson’s Disease.” This grant supports the Company’s ongoing cell-penetrant DJ-1 protein replacement therapeutic program.

Acurex Biosciences Corporation has been selected to present at the 15th annual Parkinson’s Disease Therapeutics Conference hosted by the Michael J. Fox Foundation.